ArticleThe journal of prevention of Alzheimer's disease2026
Beyond target engagement: RNA therapeutics and the neuroimmune challenge in tauopathies.
Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in RNA-based therapeutics have generated considerable interest as a strategy for targeting tau pathology in Alzheimer's disease and related tauopathies. In their review, Rajbanshi and colleagues provide a comprehensive overview of emerging RNA therapeutic modalities, translational challenges, and ongoing clinical development efforts. This commentary discusses the promise of RNA-based approaches within the broader context of contemporary neurodegeneration research, highlighting the persistent disconnect between molecular target engagement and meaningful clinical benefit. Emerging evidence suggests that successful disease modification may require consideration of neuroimmune dysfunction, biological heterogeneity, and disease stage in addition to molecular pathology. The future success of RNA therapeutics will likely depend not only on achieving precise modulation of tau biology but also on translating these advances into sustained cognitive and functional benefit for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.